Angiotensin-converting enzyme inhibitory peptides
View Patent ↗It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. More specifically, 3 tripeptides having an ACE inhibitory activity and showing a hypotensive effect in an animal experiment are discovered from a thermolysin digestion product of sesame. These tripeptides respectively have amino acid sequences Leu-Ser-Ala, Val-Ile-Tyr and Leu-Val-Tyr and show an angiotensin converting enzyme inhibitory activity.
1. A purified tripeptide consisting of an amino acid sequence selected from the group consisting of Leu-Ser-Ala and Val-Ile-Tyr.
2. An edible composition containing one or more purified tripeptides consisting of an amino acid sequence selected from the group consisting of Leu-Ser-Ala and Val-Ile-Tyr.
3. An edible composition according to claim 2 comprising from 0.001 mg to 100 mg of said tripeptides in a single intake dose.
4. An angiotensin converting enzyme inhibitor comprising from 0.001 mg to 100 mg of a purified tripeptide consisting of an amino acid sequence selected from the group consisting of Leu-Ser-Ala and Val-Ile-Tyr in a single dose for oral administration.
5. A hypotensive agent comprising from 0.001 mg to 100 mg of a purified tripeptide consisting of an amino acid sequence selected from the group consisting of Leu-Ser-Ala and Val-Ile-Tyr in a single dose for oral administration.
6. A method for treating hypertension, wherein the method comprises administering one or more tripeptides of claim 1 .
7. A method for inhibiting an angiotensin converting enzyme, wherein the method comprises allowing one or more tripeptides of claim 1 to act on the enzyme.
8. A method for suppressing elevation of blood pressure, wherein the method comprises administering one or more tripeptides of claim 1 .
9. A method for reducing blood pressure, wherein the method comprises administering one or more tripeptides of claim 1 .